EAHAD 2026 at a Glance
Get ready for EAHAD 2026. LucidQuest’s preview highlights the most relevant scientific and AI-driven developments in hemophilia and rare bleeding disorders, helping you focus on high-impact sessions and plan a smart, insight-driven agenda.
📅 Build your schedule around the topics that matter most.
📥 Download the EAHAD 2026_Preview_by_LucidQuest
Dive deeper
Key Topics from EAHAD 2026 Scientific Presentations
Emicizumab and Real-World Prophylaxis Optimization
- Pediatric real-world data point to lower annualized bleeding rates, improved joint health on MRI, and opportunities for dose optimization, supporting more cost-effective long-term prophylaxis strategies.
Gene Therapy, RNA, and Novel Molecular Therapeutics
- Long-term follow-ups from HOPE-B and GENEr8-1 are expected to reinforce sustained bleed reduction, stable factor activity, and ongoing evaluation of liver safety in hemophilia A and B.
Factor Replacement Therapies, PK, and Long-Term Outcomes
- XTEND-ed supports the durability of once-weekly efanesoctocog alfa, while Alfa-PROTECT confirms the safety and low bleeding rates of damoctocog alfa pegol, including in pediatric populations.
Non-Factor Therapies and Antibody-Based Approaches
- Marstacimab demonstrates approximately ninety-three percent joint-bleed reduction in patients with inhibitors, with strong control at target joints. Concizumab continues to position itself as a once-daily option across hemophilia A and B.
Von Willebrand Disease and Rare Coagulation Disorders
- WIL-33 highlights the role of pdVWF/FVIII prophylaxis in young children, while PopPK-WILPROPHY emphasizes personalized dosing approaches to reduce bleeds and preserve quality of life.
Clinical Management, Adherence, QoL, and Health Systems
- Advanced monitoring tools are increasingly linking prophylaxis adherence with joint protection, functional outcomes, and predictive care planning, bringing psychosocial and health-system factors into routine management.
Artificial Intelligence and Machine Learning at EAHAD 2026
Generative AI for Hemophilia Management
- Clinician-supervised AI copilots are emerging to support diagnosis, treatment planning, and safer optimization of gene therapy protocols.
AI in Social Listening for Hemophilia
- AI models are being applied to social media analysis to identify activity limitations, stigma signals, and unmet needs—informing more integrated clinical and social support strategies.
AI-Driven Insights into Physician Perspectives
- Natural language processing is being used to capture physician preferences around rebalancing agents, balancing convenience, patient-centered care, and efficacy.
AI for Standardization in Fibrinolysis Diagnostics
- AI-assisted interpretation aims to harmonize fibrinolysis assays, improving cross-laboratory consistency and protocol alignment across Europe.
AI Integration in Genetic Testing for Platelet Disorders
- New tools combine genetic variants with functional platelet assays, strengthening pathogenicity assessment in conditions such as Hermansky–Pudlak syndrome.
📅 Build your schedule around the topics that interest you.
📥 Download the EAHAD 2026_Preview_by_LucidQuest
Contact us for end-to-end conference coverage.